HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
VBI Vaccines Inc. (VBIV)
3.3  0.075  (2.33%) 01-20 01:40
Open: 3.3106 High: 3.38
Pre.close: 3.225 Low: 3.13
Volume: 6,696,605 Ave vol: 6,345,790
52w High: 6.93 52w Low: 0.69
MA(50): 3.162 MA(200): 3.339
EPS: -0.206 P/E Ratio: 0
Company profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.vbivaccines.com/
Market Cap (M): 799
Shares Out (M): 242
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
Technical analysis
Overall: Outperform
MA: Bullish MACD: Bullish
KDJ: Bullish RSI: Bullish
Target 1: 4.53 Target 2: 5.29
Resist 1: 3.88 Resist 2: 4.53
Support 1: 3.13 Support 2: 2.67
Company key metrics
Revenue per Share: 0.0186
Net Income per Share: -0.4589
Cash per Share: 0.3701
Book Value per Share: 0.7389
Price to Sales: 74.7548
Price to Book Value: 1.8813
Earnings Yield: -0.3301
Dividend Yield: 0
Debt to Equity: 0.3846
Debt to Assets: 0.2778
Financial analysis
Price to Book Value: Outperform
Return on Assets: Neutral
Return on Equity: Neutral
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Neutral
Stock Charts

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.